New drug superior to tamoxifen in blocking return of breast cancer

12/10/2004 | Wall Street Journal, The

AstraZeneca's Arimidex has shown in trials it does a much better job of preventing the recurrence of breast cancer than the popular tamoxifen, according to a study in the journal Lancet. The study, funded by AstraZeneca, said Arimidex could defend against up to 80% of the most common types of tumors that occur after menopause, compared with a 50% rate attributed to tamoxifen.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations